Pharmaceutical companies to build the core competitiveness of the marketing path.doc

 PAGE \* MERGEFORMAT 14 Pharmaceutical companies to build the core competitiveness of the marketing path Chinese medicine as a whole collapse In the time of publication of this book, the global economy is entering the ice ages, in the face of domestic high inflation, faster appreciation of the yuan, Guangdong, Zhejiang and other places a large number of export-oriented enterprises went bankrupt. It is reported that Guangdong and Zhejiang more than 20% of the enterprises have been closed. Visionary company CEOs will not be surprised for the emergence of such a situation, they should at least three years ago, began to prepare the winter jacket, if a little more foresight, they should take advantage of primitive accumulation, in the industrial value chain to find more sustainable business model; if these bosses have such a vision, today they are ‘Anta’ means ‘Huawei’, without cruelly closed fate. Back to the Chinese pharmaceutical industry, 80 years, when the once glorious moment of a large pharmaceutical company - Zhongyuan Pharmaceutical Factory gone? 90 years swept through China’s three groups, Hearts K gone? In the fast-changing Chinese market, pharmaceutical companies need to be very cautious. For whatever reason, the national pharmaceutical entrepreneurs are too concerned about the immediate competition, and too concerned about the power of leasing, and forget about deciding the survival and development of more important things - the core competitiveness. All facts indicate that there is no strategic vision, there is no sense of core competencies, the decision is indeed a business can continue to grow, whether the source of sustainable operation. Chinese pharmaceutical companies also have such examples, such as Hengrui groups, such as Fosun Pharmaceutical Group and so on, their development has witnessed the importance of strategic vision. But even the best of China’s pharmaceutical companies, not to mention the world’s leading pharmaceutical companies,